

## **AIBA AIBA Awards for 2001–2002**

All India Biotech Association (AIBA), New Delhi instituted during 1997–98 two annual awards – one for an individual scientist and the other for an industrial unit. So far, four awards under both the categories for the years 1997–98, 1998–99, 1999–2000 and 2000–2001 have been given on the occasion of annual sessions of AIBA.

For Industrial Units the AIBA awards are considered for Biotechnology innovation including launching of a new product as a result of indigenous Research and Development. It can also be granted for export performance or concept promotion. For Individual Scientists, the award is given for developing a new product through R&D work, which can be commercially exploited or which has already been commercialized. This can also be considered for the best published paper in a particular year. Up to three Awards for Individual Scientists in the field of agriculture, industrial products and healthcare are generally considered. The selections for grant of AIBA awards are done by a Selection Committee comprising eminent Scientists/Experts in the field of Biotechnology.

Entries for grant of AIBA awards for 2001–02 under the two categories, in prescribed form, may be sent to Mr. U. N. Malik, Secretary, All India Biotech Association, 'VIPPS Centre' 2, Local Shopping Centre, Block EFGH, Masjid Moth, Greater Kailash-II, New Delhi 110 048. Prescribed forms shall be sent on demand – Fax No. 011-6469166 or e-mail: unmalik@aibaonline.com.

Individual scientists and industrial units shall be considered for grant of AIBA awards only if they enroll as AIBA members. Membership application form shall also be sent along with the prescribed entry forms.

Last date for submission of entries is **20 September 2002**.

**American biotechnology company seeks to license human monoclonal antibodies directed against infectious agents affecting skin or mucosal surfaces. Preferable targets: rotavirus, human papilloma virus, Staphylococcus aureus, Chlamydia pneumoniae, Haemophilus influenzae. Others will be considered, especially if directed against microbes affecting large human populations. We are also interested in licensing novel microbial antigens with a clearly defined function in pathology and novel methods for selecting useful human anti-microbial monoclonal antibodies. Well-defined ownership of antibodies is required and preliminary clinical safety/efficacy data are desirable. Send one page description of your research by e-mail to: maristan@msn.com.**